Tamoxifen is a drug of choice for endocrine therapy of hormone receptor- positive breast cancer in women of reproductive age. The metabolic activity of tamoxifen is determined by the activity of the CYP2D6 enzyme encoded by the CYP2D6 gene: under the action of the enzyme, tamoxifen converts into the metabolically active form called endoxifen. Pharmacogenetic testing of the CYP2D6 gene in patients with hormone-positive breast cancer can help to predict response to therapy and assess the risk of side effects with the aim of improving long-term treatment outcomes.

Tamoxifen is the drug of choice for endocrine therapy of hormone receptor- positive breast cancer in women in the reproductive period.  The metabolic activity of tamoxifen is determined by the activity of the enzyme CYP2D6, encoded by the gene of the same name: under  the action of the enzyme, tamoxifen passes into the metabolically active form, endoxyphene. Pharmacogenetic testing of the CYP2D6 gene  in patients with hormone-positive breast cancer can help predict the effectiveness of therapy and assess the risk of side effects with the aim  of improving long-term treatment outcomes.

Tamoxifen is the drug of choice for endocrine therapy of hormone receptor- positive breast cancer in women in the reproductive period. The metabolic activity of tamoxifen is determined by the activity of the enzyme CYP2D6, encoded by the gene of the same name: under the action of the enzyme, tamoxifen passes into the metabolically active form, endoxyphene. Pharmacogenetic testing of the CYP2D6 gene in patients with hormone-positive breast cancer can help predict the effectiveness of therapy and assess the risk of side effects with the aim of improving long-term treatment outcomes.

Tamoxifen is one of the basic drugs of adjuvant hormone therapy in patients with hormone-dependent breast tumors. The purpose of this paper is to analyze the results of randomized trials of long-term adjuvant hormone therapy for breast cancer.

Tamoxifen is one of the basic drugs of adjuvant hormone therapy in patients with hormone-dependent breast tumors. The purpose of this paper is to analyze the results of randomized trials of long-term adjuvant hormone therapy for breast cancer.

The development of genetics in the study of predisposition to malignancies, to ovarian and breast cancers in particular, as well as the experi- ence of prophylactic surgery to reduce the risks of these diseases have permitted prophylactic bilateral tube ovariectomy to be used as a main technique in BRCA1 and BRCА2 gene mutation carriers. The purpose of this investigation is to demonstrate key studies in this area.

The development of genetics in the study of predisposition to malignancies, to ovarian and breast cancers in particular, as well as the experi- ence of prophylactic surgery to reduce the risks of these diseases have permitted prophylactic bilateral tube ovariectomy to be used as a main technique in BRCA1 and BRCА2 gene mutation carriers. The purpose of this investigation is to demonstrate key studies in this area.